Viva Pharmaceutical Inc – FDA 483, Jan 10, 2020
Viva Pharmaceutical Inc, an OTC drug manufacturer in Richmond, received a Form 483 with 14 observations following an FDA inspection from January 6-10, 2020. The observations highlight significant deficiencies across various quality system elements, including inadequate method validation, data integrity issues with electronic records, and insufficient written procedures for production, process controls, and cleaning. The findings indicate a broad lack of adherence to cGMP requirements, particularly concerning documentation, validation, and control of manufacturing processes and data.
ID · 20070fe9-ba39-4681-ae55-addb04872efc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.